Literature DB >> 9352802

Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy.

F M Laurencet1, G B Zulian, C Cabrol, D C Betticher.   

Abstract

Therapy-related myelodysplastic syndrome (t-MDS) and acute nonlymphocytic leukemia (t-ANLL) are dramatic complications of cancer chemotherapy. Drugs like plant alkaloids or antimetabolites have not been reported to cause either t-MDS or t-ANLL. Monosomy 7(-7) and trisomy 8(+8) are among the most common abnormalities in myelodysplastic syndromes. Both abnormalities in two different clones of the same patient are very rarely reported. Such a myelodysplastic syndrome occurring shortly after treatment with an antimetabolite, the adenosine analogue cladribine (1-chlorodeoxadenosine), and involved field radiotherapy is reported here.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352802     DOI: 10.1016/s0165-4608(96)00432-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

2.  Intrinsic apoptosis pathway in fallopian tube epithelial cells induced by cladribine.

Authors:  Ewelina Wawryk-Gawda; Patrycja Chylińska-Wrzos; Marta Lis-Sochocka; Kamila Bulak; Barbara Jodłowska-Jędrych
Journal:  ScientificWorldJournal       Date:  2014-11-05

3.  Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats.

Authors:  Marian Jędrych; Ewelina Wawryk-Gawda; Barbara Jodłowska-Jędrych; Patrycja Chylińska-Wrzos; Ludwik Jasiński
Journal:  Protoplasma       Date:  2013-01-24       Impact factor: 3.356

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.